P278: Type IV collagen formation/degradation ratio predicts response to infliximab induction therapy in patients with Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Bourgonje, A.R.(1);Alexdottir, M.(2);Loveikyte, R.(1);Bay-Jensen, A.C.(2);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Festen, E.A.M.(1);Weersma, R.K.(1);Karsdal, M.A.(2);Faber, K.N.(1);Mortensen, J.H.(2);Dijkstra, G.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
P279: Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study)ECCO'21 VirtualYear: 2021
Authors: Bokemeyer, B.(1);Kaiser, C.(2);Primas, C.(3);Novacek, G.(3);Biedermann, L.(4);Seibold, F.(5);Tappe, U.(6);Bettenworth, D.(7);Graw, J.(2);Hartmann, P.(8);Plachta-Danielzik, S.(9);Schultz, C.(2);
(1)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(2)Institut für Innovationsforschung, Lehrstuhl für Technologiemanagement- Christian-Albrechts-Universität zu Kiel, Kiel, Germany;(3)Medizinische Universitätsklinik Wien, Universitätsklinik für Innere Medizin III, Vienna, Austria;(4)Universitätsspital Zürich, Klinik für Gastroenterologie und Hepatologie, Zürich, Switzerland;(5)Gastroenterologische Praxis, Crohn-Colitis-Zentrum, Bern, Switzerland;(6)Gastroenterologische Gemeinschaftspraxis, Innere Medizin II- St. Barbara-Klinik Hamm, Hamm, Germany;(7)Praxis für Innere Medizin Münster, CED-Schwerpunktpraxis, Münster, Germany;(8)Gastroenterologische Gemeinschaftspraxis Minden, Fachgesellschaft für Asssitenzpersonal CED - FA-CED, Minden, Germany;(9)Kompetenznetz Darmerkrankungen, Studienabteilung, Kiel, Germany
P280: Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studiesECCO'21 VirtualYear: 2021
Authors: Ferrante, M.(1,2);Sabino, J.(1,2);Lobaton, T.(3);Dreesen, E.(4);Hoefkens, E.(5);Fierens, L.(2);Liefferinckx, C.(6);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Catholic University of Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(3)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(4)Catholic University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(5)Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium;(6)Erasme Hospital ULB, Department of Gastroenterology, Brussels, Belgium
P281: Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Deprez, N.(1);De Somer, T.(2);Baert, D.(2);Deceuninck, M.(3);Huys, I.(2);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten, E.(2);Vandervoort, J.(4);Vanheddegem, N.(2);Dewint, P.(2);
(1)UZ GENT, Gastroenterology, Tielt, Belgium;(2)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(3)AZ Sint Vincentius Deinze, Gastroenterology, Deinze, Belgium;(4)OLV Aalst, Gastroenterology, Aalst, Belgium
P282: High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel diseaseECCO'21 VirtualYear: 2021
Authors: Guo, A.(1);Ross, C.(2);Chande, N.(3);Gregor, J.(3);Ponich, T.(3);Beaton, M.(3);Khanna, R.(3);Kim, R.(4);Wilson, A.(5);
(1)Western University, Health Sciences, London, Canada;(2)Western University, Clinical Pharmacology, London, Canada;(3)London Health Sciences Centre, Gastroenterology, London, Canada;(4)London Health Sciences Centre, Clinical Pharmacology, London, Canada;(5)London Health Sciences Centre, Department of Gastroenterology, London, Canada
P283: Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study.ECCO'21 VirtualYear: 2021
Authors: de Voogd, F.(1);Van Wassenaer, E.(2);Mookhoek, A.(3);Bots, S.(1);Van Gennep, S.(1);Duijvestein, M.(1);Ponsioen, C.(1);Löwenberg, M.(1);D'Haens, G.(1);Gecse, K.(1);
(1)Amsterdam UMC- Amsterdam Medical Center- University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam University Medical Center- Emma Children's Hospital- University of Amsterdam, Pediatric Gastroenterology-, Amsterdam, The Netherlands;(3)Amsterdam UMC- VU Medical Center- VU University, Department of Pathology, Amsterdam, The Netherlands
P284: Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG)ECCO'21 VirtualYear: 2021
Authors: Thunberg, J.(1);Björkqvist, O.(1);Olén, O.(2);Ludvigsson, J.F.(3);Eriksson, C.(1);Halfvarson, J.(1);
(1)Örebro University, School of Medical Sciences, Örebro, Sweden;(2)Karolinska Institutet, Department of Medicine, Stockholm, Sweden;(3)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden; SWIBREG study group
P285: A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Weisshof, R.(1);Vavricka, S.(2,3);Pouillon , L.(4);Braegger, F.(5);Roset, M.(6);Bent-Ennakhil, N.(5);Ferrante, M.(7);
(1)Rambam Healthcare Campus, Department of Gastroenterology, Haifa, Israel;(2)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(3)Center for Gastroenterology and Hepatology AG, Center for Gastroenterology and Hepatology AG, Zürich, Switzerland;(4)Imeldaziekenhuis Bonheiden, Imelda GI Clinical Research Center, Bonheiden, Belgium;(5)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland;(6)IQVIA, Real World Solutions, Barcelona, Spain;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
P286: Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort StudyECCO'21 VirtualYear: 2021
Authors: Straatmijer, T.(1);Biemans, V.B.C.(1);Hoentjen, F.(2);de Boer, N.K.H.(3);Bodelier, A.G.(4);Dijkstra, G.(5);van Dop, W.(2);Haans, J.J.L.(6);Jansen, J.M.(7);Maljaars, P.W.J.(8);van der Marel, S.(9);Oldenburg, B.(10);Ponsioen, C.Y.(11);Visschedijk, M.C.(5);de Vries , A.C.(12);West, R.(13);van der Woude, C.J.(12);Pierik, M.(6);Duijvestein, M.(11);van der Meulen- de Jong, A.E.(8);
(1)Initiative on Crohn and Colitis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)Amsterdam University Medical Centre- Vrije Universiteit Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism AGEM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Amphia hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands;(5)University Medical Centre Groningen- University of Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(6)Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(7)Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(9)Haaglanden Medisch Centre, Department of Gastorenterology and Hepatology, The Hague, The Netherlands;(10)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(11)Amsterdam UMC- University of Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism AGEM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(12)Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(13)Franciscus Gasthuis & Vlietland, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
P288: Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Macaluso, F.S.(1);Cappello, M.(2);Crispino, F.(2);Grova, M.(2);Privitera, A.C.(3);Piccillo, G.(3);Magnano, A.(4);Ferracane, C.(4);Belluardo, N.(5);Giangreco, E.(5);Fries, W.(6);Viola, A.(6);Di Mitri, R.(7);Mocciaro, F.(7);Camilleri, S.(8);Garufi, S.(8);Renna, S.(1);Casà, A.(1);Maida, M.(8);Orlando, A.(1);
(1)Ospedali Riuniti Villa Sofia-Cervello, Department of Medicine, Palermo, Italy;(2)University of Palermo, Gastroenterology & Hepatology Section- Promise-, Palermo, Italy;(3)“Cannizzaro” Hospital, Inflammatory Bowel Disease Unit, Catania, Italy;(4)“Vittorio Emanuele” Hospital, Gastroenterology Unit, Catania, Italy;(5)“Guzzardi” Hospital, Gastroenterology Unit, Vittoria, Italy;(6)'G. Martino” Hospital, Inflammatory bowel disease Unit, Messina, Italy;(7)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Uni, Palermo, Italy;(8)“S. Elia- Raimondi” Hospital, Gastroenterology and Endoscopy Unit-, Caltanissetta, Italy Sicilian Network for Inflammatory Bowel DIseases (SN-IBD)
P289: A French nationwide prospective study on patients with Crohn’s disease and ulcerative colitis treated with Infliximab-biosimilar CT-P13 in a real-life setting: two-year follow-up of the ReFLECT studyECCO'21 VirtualYear: 2021
Authors: Bouhnik, Y.(1);Nancey, S.(2);Assing, M.(3);Mammar, N.(3);Laharie, D.(4);
(1)CHU Beaujon, Gastroenterology, Clichy, France;(2)CHU Lyon, Gastroenterology, Lyon, France;(3)Pfizer, Inflammation & Immunology, Paris, France;(4)CHU Bordeaux Haut-Lévêque Hospital, Gastroenterology, Pessac, France
P290: Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Ungaro, R.(1);Kadali, H.(2);Zhang, W.(3);Adsul, S.(4);Reinisch, W.(5);
(1)The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States;(2)Takeda, Global Patient Safety and Evaluation, Cambridge, United States;(3)Takeda, Statistical and Quantitative Science, Cambridge, United States;(4)Takeda, Global Medical Affairs, Zurich, Switzerland;(5)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria
P291: Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group studyECCO'21 VirtualYear: 2021
Authors: Lee, C.(1);Tang, Y.(1);Schroeder, C.(1);Zhang, J.(1);Nguyen-Cleary, T.(1);Mullin, S.(1);Ma, M.(1); Lyon, N.(1);Grundy, J.(1);
(1)Arena Pharmaceuticals- Inc., n/a, San Diego, United States
P292: Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysisECCO'21 VirtualYear: 2021
Authors: Sleutjes, J.A.M.(1);Roeters van Lennep , J.E.(2);Boersma , E.(3);de Vries , A.C.(1);van der Woude , C.J.(1);
(1)Erasmus Medical Center, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus Medical Center, Internal Medicine, Rotterdam, The Netherlands;(3)Erasmus Medical Center, Clinical Epidemiology of Cardiovascular Diseases, Rotterdam, The Netherlands
P293: Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical studyECCO'21 VirtualYear: 2021
Authors: Vieujean, S.(1);Loly, J.P.(1);Boutaffala, L.(1);Pariente, B.(2);Reenaers, C.(1);Briquet, A.(3);Lechanteur, C.(3);Beguin, Y.(4);Louis, E.(1);
(1)CHU of Liège- University of Liège, Department of Gastroenterology, Liège, Belgium;(2)Hopital Claude Huriez- Université Lille 2, Department of Gastroenterology, Lille, France;(3)CHU of Liège- University of Liège, Laboratory of Cell and Gene Therapy LTCG, Liège, Belgium;(4)CHU of Liège- University of Liège, Department of Hematology, Liège, Belgium
P294: AMT-101, a gut selective oral IL-10 fusion: results from a Phase 1b study in patients with active Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Posch, M.(1);Tanase, R.(2);Maisaia, K.(3);Jucov, A.(2);Geier, C.(1);Hotson, D.(4);Hamdy, O.(5);Whitney, J.A.(4);Garovoy, M.(6);Kanwar, B.(6);Schreiber, S.(7);
(1)Charité Research Organisation GmbH, Medicine, Berlin, Germany;(2)Arensia Exploratory Medicine- Republican Clinical Hospital 'Nicolae Testemitanu', Gastroenterology, Chisinau, Moldova- Republic Of;(3)Arensia Exploratory Medicine LLC, Gastroenterology, Tbilisi, Georgia;(4)Applied Molecular Therapeutics, Preclinical and Translational medicine, South San Francisco, United States;(5)Applied Molecular Therapeutics, Program Management, South San Francisco, United States;(6)Applied Molecular Therapeutics, Clinical Development, South San Francisco, United States;(7)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany
P295: Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Maniero, D.(1);Lorenzon, G.(1);Marsilio, I.(1);Rigo, A.(1);Cardin, R.(1);Facchin, S.(1);Barberio, B.(1);D'Incà, R.(1);Zingone, F.(1);Bahur, B.(2);Bray, K.R.(3);Savarino, E.V.(1);
(1)University of Padova, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(2)ProciseDx, Department of Clinical Trial, San Diego, United States;(3)ProciseDx, Department of Clinical Development and Medical Affairs, San Diego, United States
P296: Stopping 5-aminosalicylic acid in patients with ulcerative colitis who are in clinical remission does not increase risks of flareECCO'21 VirtualYear: 2021
Authors: Mak, J.W.Y.(1);Yuen, N.T.K.(1);Yip, T.C.F.(1);Lam, R.H.M.(1);Lam, B.K.H.(1);Chan, F.K.L.(1);Ng , S.C.(1);
(1)The Chinese University of Hong Kong, Medicine and Therapeutics, Shatin, Hong Kong- China
